All In Biotech

Drug Trial Radar · NCT06159478

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer

Phase II Investigator-initiated Trial of Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jun 30, 2023

Primary completion

Feb 28, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
National Cancer Center, JapanGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Dec 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.

Conditions

  • Low-grade Glioma
  • Pancreatic Cancer

Interventions

  • Binimetinib 15 MGDrug

    Binimetinib 45mg is orally administered twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (centrally assessed)Time frame: Baseline up to 4 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan · Recruiting

  • Tohoku university Hospital

    Sendai, Miyagi, Japan · Recruiting

  • National Cancer Center Japan

    Chuo-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.